

# Transcript of the Sheku Bayoh Inquiry

Wednesday, 10 May 2023

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

(10.00 am)  
  
(10.29 am)

(Delay in proceedings)

DR KERRYANNE SHEARER (continued)

Questions from MS GRAHAME (continued)

LORD BRACADALE: Ms Grahame.

MS GRAHAME: Thank you very much. Dr Shearer, yesterday at the end of the day we had move on to look at your final post mortem report, you will still have the hard copy in front of you, and that is PIRC 01445 and we had started looking at the conclusions section on page 15.

So I think yesterday, just to recap, you had explained your role as a forensic pathologist: you were trying to identify an explanation for the death of Mr Bayoh. And you had taken us through the information about the circumstances that you were furnished with and you took us through the post mortem examination itself, plus the further investigations that were carried out: toxicology, virology, these things, and radiology. You had talked about the skeletal survey, the x-ray, the CT scan and you put all of that information together and this section, pages 15 to 17 of your final report, essentially brings all of that information together, and then you drew your conclusion as to the explanation for

## Transcript of the Sheku Bayoh Inquiry

1           Mr Bayoh's death.  When I say "you", I also mean you and  
2           your colleague, Dr Bouhaidar, who -- it was  
3           a double-doctor post mortem as you said?

4           A.  Yes.

5           Q.  You both agreed on that conclusion?

6           A.  Yes.

7           Q.  Thank you.  I would like to look today at those sections  
8           of the report, so pages 15 to 17 if you may.  And I am  
9           particularly interested in trying to draw out the  
10          factors that you thought were significant.

11          When the Chair comes to considering your evidence in  
12          light of all the evidence he has heard, he will wish to  
13          consider whether something played a part in the death  
14          and to what extent it maybe played a part.

15          So if I may, I would like to begin by going through  
16          these pages by identifying things that you said didn't  
17          have any role to play.  So these are things presumably  
18          that you were satisfied in your examination that could  
19          be dismissed, so the Chair can maybe take the view that  
20          they can be dismissed.

21          A.  Okay.

22          Q.  So looking first of all on page 15, paragraph 2 on that  
23          page, the first paragraph is just your summary of the  
24          circumstances which you have described yesterday.

25          A.  Yes.

## Transcript of the Sheku Bayoh Inquiry

- 1 Q. Paragraph 2 says:
- 2 "Post mortem examination showed no evidence of
- 3 natural disease that would have played any role in death
- 4 here. The thyroid gland was enlarged but not to such an
- 5 extent that it would have caused airway compromise."
- 6 I think on the previous pages of your report, pages
- 7 12 and 13, you have gone through various results from
- 8 tests, you've looked at areas in the body where there
- 9 may have been natural disease, pre-existing natural
- 10 disease, you've considered the results of the
- 11 investigations, the virology, the histology,
- 12 the microbiology, that type of thing and I think
- 13 yesterday you said you couldn't find any natural disease
- 14 that would explain Mr Bayoh's death?
- 15 A. That's correct, yes.
- 16 Q. And the two things we specifically talked about
- 17 yesterday, the enlarged thyroid, but you explained that
- 18 the results didn't indicate any significant issue with
- 19 that?
- 20 A. Uh-huh.
- 21 Q. And I also asked you quite a number of questions about
- 22 whether he had heart disease and I think you excluded
- 23 that as a possibility?
- 24 A. Yes.
- 25 Q. And the Chair's got your evidence on that yesterday.

## Transcript of the Sheku Bayoh Inquiry

1           The second thing as I understand it that you looked for  
2           but couldn't find, and I think you sum that up in  
3           paragraph 3 of page 15, and if we can look at the very  
4           final sentence there, you said:

5                     "Notably there was no evidence of injury to the body  
6           that would account for death here."

7           A. Yes.

8           Q. I think yesterday you talked about examining the body  
9           for some sort of primary injury, primary cause,  
10          blunt-force injury or sharp-force injury --

11          A. Yes.

12          Q. -- that could have been a complete explanation for his  
13          death?

14          A. Yes.

15          Q. There was no signs of that at all?

16          A. No.

17          Q. I think we went through yesterday in quite some detail,  
18          pages 5 to 8 were external, the external examination and  
19          pages 8 to 10 of your report were the internal  
20          examination.

21          A. Yes.

22          Q. So thorough inside and out, no signs whatsoever --

23          A. Yes.

24          Q. -- of an injury? And then the third thing that I think  
25          you note, and this is actually on page 16 of your

## Transcript of the Sheku Bayoh Inquiry

- 1 report, and if we look at paragraph 3, so you also  
2 considered -- and this related to CS and PAVA spray?
- 3 A. Yes.
- 4 Q. You explained yesterday on page 4 of your report you  
5 detailed the circumstances and you noted from what you  
6 had been told about the events at Hayfield Road that  
7 Mr Bayoh -- officers had discharged their CS and PAVA  
8 sprays and they had tried to spray him with those  
9 chemicals.
- 10 A. Uh-huh.
- 11 Q. I think let's look at this paragraph on page 16 then.  
12 You say you considered:  
13 "With regards to the role PAVA and/or CS sprays may  
14 have played in death~..."
- 15 You had mentioned the information, that you had been  
16 provided that police officers had used these substances  
17 and they:  
18 "... had no immediate effects on Mr Bayoh."
- 19 A. Yes.
- 20 Q. Obviously the evidence -- the Chair has heard a lot of  
21 evidence about the circumstances but presumably you  
22 would agree that he will have to consider what he thinks  
23 happened --
- 24 A. Absolutely.
- 25 Q. -- at the scene and that would be a relevant factor for

## Transcript of the Sheku Bayoh Inquiry

1           the Chair in deciding how he views the impact of PAVA or  
2           CS?

3           A. Absolutely, yes.

4           Q. Then you have also said -- you have commented on  
5           evidence of one civilian witness, and then you say:

6                   "From the literature available, it would appear  
7           specific side-effects include bronchospasm and ..."

8                   Forgive me the pronunciation of this:

9                   "... laryngospasm ..."

10          A. Bronchospasm and laryngospasm, yes.

11          Q. "... and patients with pre-existing respiratory disease  
12          (which did not appear to be the case here) are more at  
13          risk from severe effects."

14                 Tell me, in relation to those conditions, did you  
15          look for signs of either of those conditions?

16          A. There was no evidence that Mr Bayoh had any pre-existing  
17          conditions that would have led to these side-effects and  
18          I wasn't given any information in either the general  
19          practice notes or the medical notes so suggest that you  
20          had previously been diagnosed with anything. Conditions  
21          like asthma and bronchitis are the kind of classical  
22          ones.

23          Q. So you looked at the GP and the hospital notes as  
24          I understand it?

25          A. Yes.

## Transcript of the Sheku Bayoh Inquiry

- 1 Q. Did you find anything in those that indicated he had  
2 a pre-existing issue with his respiratory system?
- 3 A. No.
- 4 Q. Yesterday you talked about the lungs. I think we  
5 referred on page 9, you talked about -- let me see ...  
6 you talked about the chest on page 9 of your report, you  
7 talked about various areas but in the first paragraph  
8 under, "Chest", on page 9 you said:  
9 "The lungs ..."  
10 You talked about the weight of the right and the  
11 left, you talked about them being congested, but you  
12 said there was no evidence of any pulmonary  
13 thromboembolism and I think yesterday, if I'm right, you  
14 said there was no evidence of any disease process taking  
15 place there?
- 16 A. Yes.
- 17 Q. If we also look at page 13, under, "Histology", you will  
18 see an entry "Lung", and you say:  
19 "There are extensive congestive features in areas of  
20 pulmonary oedema, there are widespread areas of  
21 subpleural chronic inflammation and pigment laden  
22 macrophages."  
23 A. Yes.
- 24 Q. Is there anything in that from the histology that would  
25 give rise to any concerns on your part that there was

## Transcript of the Sheku Bayoh Inquiry

1 pre-existing problem?

2 A. No.

3 Q. Can you tell me, if you are looking in a post mortem for  
4 signs of the bronchospasm or the laryngospasm are there  
5 signs that would be obvious to you, either on  
6 examination or through further investigations and tests  
7 that you could point to, that had he suffered from  
8 anything like that?

9 A. Not necessarily, it is not something that is very easy  
10 to diagnose at post mortem. It basically is a -- the  
11 muscles around the cartilage of the neck and the throat  
12 go into a spasm and the muscles in the lungs go into  
13 a spasm, so it is very much the person becomes very,  
14 very breathless, can't breathe, becomes very, very  
15 wheezy. So there is a very kind of clear clinical  
16 pattern that is involved with it that wasn't reported in  
17 this case.

18 Q. So there was nothing from your consideration of any of  
19 the information you were given which indicated there had  
20 been breathlessness or wheezing noted in relation to  
21 Mr Bayoh?

22 A. If people have chronic problems, what we can see down  
23 the microscope are specific changes in the cells, we can  
24 see changes in the muscles, and changes in the lung  
25 cells which wasn't present in this case.



## Transcript of the Sheku Bayoh Inquiry

1 Q. So nothing like that that you could find?

2 A. Yes.

3 Q. We may hear further evidence about the impact of sprays  
4 on a person but from your own perspective as a forensic  
5 pathologist could you find anything at all?

6 A. No.

7 Q. Then the fourth issue which you raise is on page 16, and  
8 it is paragraphs 4 and 5. This relates to  
9 excited delirium. So this is the fourth area, and if we  
10 could have that on the screen, 4 first. You have said  
11 here:

12 "Given the circumstances provided, toxicological  
13 findings and lack of another cause of death at  
14 post mortem, the possibility of excited delirium  
15 syndrome has been considered in this case."

16 So this was something that you did consider as part  
17 of your overall assessment?

18 A. Yes.

19 Q. Is that correct:

20 "It is however a psychiatric and not a pathological  
21 diagnosis~..."

22 Could you explain to the Chair what you meant by  
23 that, it's a psychiatric not a pathological diagnosis?

24 A. It's a psychiatric syndrome that needs to be diagnosed  
25 by a psychiatrist, it is not a diagnosis that I can

## Transcript of the Sheku Bayoh Inquiry

1           prove pathologically. I can't relate anything to the  
2           cause of death unless I can prove it pathologically,  
3           unless I have pathological evidence, and this isn't  
4           because it is very much based on information that you  
5           have about the case and things that you are finding, but  
6           you can't tie it all together pathologically, so it's in  
7           the psychiatric community and not something that we  
8           would diagnose.

9           Q. So in terms of your external examination of the body, is  
10          there anything you could find that would be  
11          an indication of excited delirium?

12          A. No, no.

13          Q. And from your internal examination of the body, is there  
14          anything you could see?

15          A. No, no.

16          Q. And from any the tests that you instructed to be carried  
17          out, and the further investigations, is there any sort  
18          of result or anything that could indicate that that had  
19          occurred?

20          A. The reason it's discussed in the first place is because  
21          of the toxicological results because often this syndrome  
22          is described with a background of someone who is  
23          intoxicated with particular drugs, particularly  
24          stimulant drugs, so that is one of the reasons that it  
25          has been discussed in the first place because of what we

## Transcript of the Sheku Bayoh Inquiry

1           have found toxicologically and because of the  
2           circumstances that we have been given surrounding the  
3           case. That is the main reason for discussion.

4       Q. So you have talked about the toxicological results and  
5           the Alpha-PVP and MDMA. Because those were found in the  
6           samples carried out and tested, that has resulted in  
7           your mentioning this at all in this part of the report?

8       A. Yes.

9       Q. But essentially there is no test that you personally  
10           could carry out as part of the post mortem or further  
11           tests that could identify excited delirium as  
12           a condition?

13      A. No, I would never diagnose it as a pathologist.

14      Q. So is that why you say it's psychiatric and not  
15           pathological?

16      A. Exactly.

17      Q. Then you go on to say there in that paragraph:

18                 "... there is some debate in the forensic community  
19                 with regards to its application as a cause of death."

20                 Could you tell us about that?

21      A. Mainly in America forensic physicians or pathologists  
22           may use this as a cause of death whereas in the UK no  
23           forensic pathologists would use it as a cause of death  
24           so that is where the difference in the forensic  
25           community and the application comes from.

## Transcript of the Sheku Bayoh Inquiry

- 1 Q. So there is a clear distinction between the practice in  
2 America and the practice in the UK, you say?
- 3 A. Yes.
- 4 Q. Not just in Scotland?
- 5 A. No, no, in the UK as a whole.
- 6 Q. I wonder if you could have a look at something for me.  
7 It's WIT 00025. It will come up on the screen. This is  
8 guidance I would like to ask you about at this stage.  
9 So this is released -- at the top it says "Forensic  
10 science regulator", and the Royal College of  
11 Pathologists; is the Royal College a UK-based  
12 Royal College?
- 13 A. It is, yes, all pathologists should be a member of the  
14 Royal College of Pathologists.
- 15 Q. Sorry, did you say all?
- 16 A. All pathologists who are practising, so I am a member of  
17 the Royal College of Pathologists, yes.
- 18 Q. Is that all pathologists in the UK?
- 19 A. Yes.
- 20 Q. Can we just move down the page please. We see this is  
21 the guidance from the Forensic Science Regulator and it  
22 says, "The use of excited delirium as a cause of death".  
23 Issue 2, and so -- as a member of that Royal College do  
24 you have regard -- are you informed about these --
- 25 A. Yes.

## Transcript of the Sheku Bayoh Inquiry

- 1 Q. -- guidance notes?
- 2 A. We know about the guidelines, yes.
- 3 Q. Do you have regard to them, do you follow that guidance?
- 4 A. Yes, we should do, yes.
- 5 Q. So if we can move up the page, please. It's only seven  
6 pages long but I will take you to some of the paragraphs  
7 I would like to refer to. Stop there for a second. We  
8 see it is published in -- just move up a little bit --  
9 published in 2020. So this didn't exist at the time in  
10 2015 when you were doing the post mortem?
- 11 A. No.
- 12 Q. It has been issued subsequently. If we can move down  
13 first of all to paragraph 1.1.1, section 1. It says:  
14 "The Forensic Science Regulator ... became aware of  
15 concerns, raised outside this jurisdiction, about the  
16 use, and potential misuse, of 'excited delirium' as  
17 a cause of death. Advice was therefore sought from the  
18 Forensic Pathology Specialist Group ... and the Forensic  
19 Pathology Speciality Advisory Committee ... of the  
20 Royal College of Pathologists."  
21 It goes on to say:  
22 "It is clear the term 'excited delirium' has  
23 relatively rarely been used as a sole cause of death in  
24 this jurisdiction but it appears that it has occurred."  
25 Is that something you are aware of, that it has been

## Transcript of the Sheku Bayoh Inquiry

1           used in Scotland?

2           A. Not in Scotland, no. I'm not aware that it had been  
3           used in Scotland. I don't know of any colleagues that  
4           would use that term as a cause of death.

5           Q. If we can move up the page, please. At 1.1.4 it says:

6                     "After the consideration of this issue was underway  
7           it became clear that the Independent Review of Deaths  
8           and Serious Incidents in Police Custody chaired by  
9           Rt Hon Dame Elish Angiolini ... might address concerns  
10          about this issue. The report published by the  
11          review~... did address this issue and made the following  
12          recommendation.

13                    "'Excited Delirium' should never be used as a term  
14          that, by itself, can be identified as the cause of  
15          death. The use of Excited Delirium as a term in  
16          guidance to police officers should also be avoided'."

17                    So it would appear that was a recommendation from  
18          a review by Dame Elish Angiolini, and this was  
19          considered, was it, by the Royal College of  
20          Pathologists?

21          A. Yes, it's one of their guidelines.

22          Q. It is likely that we will be hearing further evidence  
23          about this at a later hearing so I won't ask you to go  
24          into that in any detail. Can we move down, please,  
25          I would like to look at 2.1.1. It says:

## Transcript of the Sheku Bayoh Inquiry

1            "This guidance ... applies to forensic pathologists  
2            in England Wales and Northern Ireland."

3            It doesn't mention Scotland.

4            A. We have our own Code of Practice that is currently being  
5            updated. It is not dissimilar, to be fair. The reason  
6            it has to be separate is because we have a different  
7            legal system and a lot of the legalities are mentioned  
8            in the Code of Practice so we do have a separate  
9            Scottish Code of Practice. But I am aware and have read  
10           the English Code of Practice and there is some crossover  
11           in the people who input to both. So it's not dissimilar  
12           to the English and Northern Ireland Code of Practice.

13           Q. You just said in any event you would follow guidance  
14           from the Royal College; you are a member?

15           A. Absolutely, yes.

16           Q. I see at 3.1.1, this:

17                    "... became effective on 31 October 2020."

18                    Can we look at section 5 now, please. 5.1.1 says:

19                    "The use of the term 'Excited Delirium' as a sole  
20                    cause of death should not be used."

21                    From the perspective of a forensic pathologist  
22                    I note in the cause of death you have given -- we have  
23                    touched on this yesterday -- in your final post mortem  
24                    report, the words "excited delirium" do not appear as  
25                    the cause of death.

## Transcript of the Sheku Bayoh Inquiry

1 A. No.

2 Q. So in effect were you -- is this a phrase or the  
3 words -- you wouldn't use that as a cause of death?

4 A. No, no.

5 Q. So you have been following that advice even before this  
6 guidance came out?

7 A. To be fair, I can't remember what the guidance was back  
8 in 2015 but chances are it probably wasn't dissimilar.  
9 But I can't remember what that possibly was, but it has  
10 never been a syndrome that forensic pathologists in the  
11 UK should have generally used, and we are educated  
12 during training that it is not something you use as  
13 a cause of death.

14 Q. Thank you. It goes on to talk about:

15 "The term has caused controversy~..."

16 We have certainly heard it is a controversial term  
17 in this hearing, we will hear more about that I think  
18 from another witness, and it mentions particularly in  
19 North America. Is that what you were --

20 A. That is the cases I am aware of, yes.

21 Q. So:

22 "... in North America, where it has been applied in  
23 some cases where other important pathological  
24 mechanisms, such as positional asphyxia and trauma may  
25 have been more appropriate descriptions. It is



## Transcript of the Sheku Bayoh Inquiry

1           recognised that the physiological condition  
2           characterised by physical agitation and altered mental  
3           state commonly brings individuals into contact with  
4           police and other emergency personnel, and is an acutely  
5           life threatening one. This conditions which is usually  
6           drug induced needs to be recognised and treated."

7           Do you want to talk about that at all?

8           A. I have put -- that is a very similar paragraph, I have  
9           said exactly that in my confusion -- sorry, in my  
10          conclusion. Individuals suffering from this condition  
11          because they are very agitated they become very  
12          aggressive, they are very difficult to manage, they are  
13          often -- they come to the attention of medics, and  
14          police have to be involved because they are a danger to  
15          themselves and a danger to other people.

16          So often they come into that scenario and police are  
17          involved and a restraint is required and that is often  
18          why they then come to our attention and we have found,  
19          and the literature will show, that in the vast majority  
20          of these cases they have drugs in their system that may  
21          explain their behaviour also, and why they have come  
22          into contact with the police. So this is why it's  
23          a very particular scenario, and why in this case the  
24          circumstances entirely fitted with that particular  
25          scenario hence why the discussion had to be had in the

## Transcript of the Sheku Bayoh Inquiry

1 conclusion, but would never have been involved in the  
2 cause of death.

3 Q. Thank you. Then it says at 5.1.3:

4 "Formulating the cause of death in these  
5 circumstances can be difficult. The regulator and the  
6 Royal College advise pathologists to consider  
7 an approach where the central cause of the fatal  
8 clinical condition is offered as an immediate cause of  
9 death and, where appropriate, used in conjunction with  
10 a term capturing the altered physiological and  
11 psychological state. Examples could include  
12 'amphetamine intoxication with acute behavioural  
13 disturbance' or 'cocaine cardio-toxicity and psychosis."

14 I just wanted to talk to you about that suggestion.  
15 When it says advises pathologists to consider  
16 an approach where the central cause of the fatal  
17 clinical condition is offered as an immediate cause of  
18 death, was that what you were talking about yesterday as  
19 having the main cause of -- the physical cause of death  
20 at the top, number 1?

21 A. Yes. Uh-huh. In these cases, and I think you can  
22 probably see that with what their suggestions are, it is  
23 very, very difficult to give a 1a, 1b, 1c cause of  
24 death, it just doesn't fit in that system because there  
25 are so many issues involved and there's so many things

## Transcript of the Sheku Bayoh Inquiry

1           going on. So in these cause of deaths ideally what we  
2           try to do is to give a narrative cause of death, so it  
3           tends to be a sentence that includes everything that we  
4           think is important because it doesn't fit into the usual  
5           pattern.

6           Q. Can you explain why excited delirium doesn't appear  
7           anywhere in the cause of death that you certified after  
8           the post mortem, not even on line 2 or anything?

9           A. Because it is not a pathological diagnosis, it's  
10          a psychiatric diagnosis. So it's not a diagnosis that  
11          I can make, so I would never put it in my cause of  
12          death.

13          Q. Thank you. Looking at 5.1.4 it says:

14                 "Discussion of Excited Delirium may better be  
15          covered within the commentary section of the post mortem  
16          report."

17                 Is that in fact the section you have called  
18          "Conclusions"?

19          A. Yes.

20          Q. Where you do raise it and you discuss it there?

21          A. Yes, exactly.

22          Q. And that is what you have done. Thank you. We can move  
23          back to page 16, please of your final post mortem  
24          report. We were on paragraph 4. Just carrying on there  
25          you say:

## Transcript of the Sheku Bayoh Inquiry

1            "That said, there is a great deal of literature  
2            looking at this syndrome especially with regards to the  
3            circumstances described in this case, but it has to be  
4            remembered that it should be considered in conjunction  
5            with circumstantial information (namely a history of  
6            restraint) and toxicological findings."

7            Can you help the Chair understand what is the  
8            significance of these circumstances and the  
9            toxicological findings?

10          A. When people come into -- when people have this sort of  
11          kind of presentation with the agitation and the  
12          aggression and they come into contact with medical  
13          personnel and often police, then they will be managed in  
14          a particular way which normally will be a degree of  
15          restraint for their safety and for the safety of others.  
16          But that restraint in itself can pose problems depending  
17          on how it is undertaken in terms of how the person is  
18          restrained, if that affects their airway, if that leads  
19          to a degree of positional or mechanical asphyxia, as we  
20          discussed yesterday. So I have to take into  
21          consideration the background circumstances and what I am  
22          told has actually been happening in the whole situation  
23          and look at the witness statements, and then what I'm  
24          finding at post mortem to support or exclude exactly  
25          what may have happened with regards to the restraint.

## Transcript of the Sheku Bayoh Inquiry

1           Then in addition to that you have the toxicological  
2           information because often with toxicology, with  
3           particular drugs, even just having those drugs on board  
4           in the first place can kill someone regardless of them  
5           being involved in this whole situation. So it's very  
6           much a bigger picture scenario where you have to have  
7           all of the information with all of the findings at the  
8           post mortem, all of the toxicological tests, in order to  
9           come to a conclusion as to what has been the significant  
10          factors in someone dying.

11         Q. So would your evidence be that when the Chair is  
12          considering what happened here and what caused  
13          Mr Bayoh's death, that it will be necessary for him to  
14          look at all of the circumstances, what happened,  
15          including the results from your post mortem and the  
16          investigations you did?

17         A. Absolutely.

18         Q. And not to simply look at your evidence in a vacuum?

19         A. No. No.

20         Q. Thank you.

21         A. My post mortem again takes into account the information  
22          that I had been given about the background  
23          circumstances, so that is incorporated into kind of  
24          everything I have done and especially into the  
25          conclusion and the cause of death, so I needed that

## Transcript of the Sheku Bayoh Inquiry

1 information in the first place.

2 Q. It has been an integral part of your process in reaching  
3 a conclusion about cause of death?

4 A. Absolutely.

5 Q. And you think that is much to commend it?

6 A. Uh-huh.

7 Q. Let's look at this next paragraph 5 on page 16:

8 "Excited delirium syndrome is described as  
9 a life-threatening condition that has a variety of  
10 causes but is largely associated with drug  
11 intoxication~..."

12 You have mentioned earlier the significance of the  
13 association with drug intoxication. I'm interested in  
14 this comment about it being a life-threatening condition  
15 that has a variety of causes. Can you tell us a little  
16 bit more about that?

17 A. It can result in sudden death. There is a reasonable  
18 amount of literature surrounding this where people who  
19 are involved in this sort of situation with drugs  
20 on board can die suddenly in the process of them being  
21 restrained or not. So it is a life-threatening  
22 condition that has to be considered and it is -- it will  
23 be something that's taught to medics as well for people  
24 who are presenting because people can die from this and  
25 they will see people dying in hospital. It has -- the

## Transcript of the Sheku Bayoh Inquiry

1           variety of causes is kind of based around again the  
2           circumstances, the drugs on board, what happens to them  
3           when they present, how they're managed after they  
4           present, so there is a number of things surrounding that  
5           that again have to be taken into consideration if they  
6           do die suddenly.

7           Q.   So a life threatening condition with a variety of  
8           causes, and you say largely associated with drugs:  
9                 "... in particular stimulant drugs~..."

10           And you have noted that MDMA and Alpha-PVP are both  
11           stimulant drugs?

12           A.   Yes.

13           Q.   If it is a life-threatening condition associated with  
14           drug intoxication and we have those stimulant drugs  
15           present in the samples that were tested, you told us  
16           that yesterday, is there anything that can be seen in  
17           the post mortem externally, internally or in terms of  
18           the toxicology, for example, that would allow you to  
19           say: this person's presentation is such that I can see  
20           signs in my post mortem examination that they were about  
21           to drop down dead suddenly?

22           A.   No.   And that's the thing about drug deaths is often  
23           they just present dead, there is no kind of -- nothing  
24           leading up to that, and on post mortem examination the  
25           main thing that we find are drugs in the system, we

## Transcript of the Sheku Bayoh Inquiry

1 don't often find anything to say why they've died at  
2 that particular time, it's we have to assume that the  
3 drugs have a significant effect on their heart and can  
4 cause a sudden cardiac arrest. So we don't -- we often  
5 don't find anything that I suppose backs up that drugs  
6 have been the cause of death here, but that tends to be  
7 because they die very, very suddenly from that.

8 Q. In terms of the suddenness of the death, from your  
9 experience as a forensic pathologist, have you seen any  
10 signs -- on cases where people have died suddenly, have  
11 you sign any signs in the examination or from the  
12 results which are commonly seen in cases where people  
13 die suddenly?

14 A. Not commonly. People with -- who die -- are we talking  
15 specifically stimulant drugs or in general drugs?

16 Q. We could look at the stimulant drugs MDMA and Alpha-PVP.

17 A. So specifically with stimulant drugs often you won't see  
18 anything. If you do, what you can sometimes see is if  
19 they have chronically used such drugs you can see  
20 chronic changes in the heart or in the coronary vessels.  
21 If there has been a period of resuscitation beforehand  
22 what you can also see sometimes is some damage to the  
23 heart muscle, very, very early damage. When the heart  
24 is going into cardiac arrest and kind of behaving  
25 erratically there is very much a surge of adrenaline and



## Transcript of the Sheku Bayoh Inquiry

1           noradrenaline going through the system and this can  
2           cause damage to the heart that we can sometimes see  
3           microscopically but it is very, very rarely that we see  
4           that. The vast majority of our stimulant drugs-related  
5           cases we probably won't see anything at the time of the  
6           post mortem. Ultimately nine times out of ten they are  
7           in younger people who have a negative post mortem and  
8           it's the toxicology that will then gives the answer.

9           Q. When you say toxicology will give us the answer, in what  
10          way does toxicology give the answer?

11          A. So we will look for a variety of drugs, and the results  
12          from that will be a drug or several drugs that we know  
13          can kill someone acutely if they have taken that drug.  
14          So if we have nothing else at post mortem that can  
15          explain the person's death, and a certain kind of set of  
16          circumstances that fits as well, then we have to  
17          conclude that the person has died because of the drug  
18          toxicity.

19          Q. And in terms of what you would expect if a person has  
20          died exclusively from drug toxicity, stimulant drug  
21          toxicity, what would you expect to find in terms of  
22          readings in relation to that stimulant drug or is there  
23          no commonality?

24          A. Again, it varies depending on the individual because  
25          different drugs will affect different people in

## Transcript of the Sheku Bayoh Inquiry

1           different ways. With stimulant drugs in particular you  
2           don't necessarily have to have a high level of the drug  
3           in your system for it to cause ill effects. Stimulant  
4           drugs in particular are not dose-dependent, are not  
5           level-dependent so you can have a reasonably low level  
6           of drugs like ecstasy or cocaine, amphetamine, and it  
7           doesn't necessarily mean that the drug hasn't killed  
8           them, whereas there are other drugs that kill people in  
9           different ways that we look for particular levels that  
10          maybe are in toxic and fatal ranges and we have various  
11          kind of medical papers and research that we can use to  
12          kind of look at that. But from a stimulant point of  
13          view it very much is not dose-dependent and what --  
14          a level that can kill someone may not kill someone else.  
15          It is very person-dependent as well.

16        Q. So there is no fatal dose that as soon as you get to  
17          that concentration the risk is there of dying suddenly?

18        A. Not a fixed one for every person. It is so variable  
19          from individual to individual. There will be papers  
20          that will have looked at cases of various drugs and what  
21          their levels have been in their toxicology when they  
22          have died, so there are published papers and there are  
23          very good books that look at ranges of therapeutic,  
24          toxic and fatal levels of various drugs which we do use  
25          on a regular basis. But when it comes to stimulants, if

## Transcript of the Sheku Bayoh Inquiry

1           they are there, then they could potentially have killed  
2           someone.

3       Q.   Even at a relatively low dose?

4       A.   Yes.

5       Q.   You mentioned a moment ago in certain cases you might  
6           see chronic changes in the heart?

7       A.   Yes.

8       Q.   Did you see any of those here?

9       A.   No.

10      Q.   You mentioned that resuscitation, if that had taken  
11          place, might cause damage to the heart.  Did you see any  
12          signs of that here?

13      A.   No.

14      Q.   And you also mentioned adrenaline and noradrenaline can  
15          cause damage to the heart.  Did you find any signs of  
16          that here?

17      A.   No.

18      Q.   Moving back to paragraph 5 on page 16.  Continuing to  
19          read there:

20                 "It can include paranoid and aggressive behaviour as  
21                 was reported in this case and has no pathognomonic ..."

22                 I will leave you to say the long words:

23                 "... no ... findings at post mortem."

24                 Can you explain what that means?

25      A.   That is what I was talking about, as in a pathological

## Transcript of the Sheku Bayoh Inquiry

1 diagnosis as opposed to a psychiatric diagnosis. There  
2 is no -- there is nothing specifically that we can see  
3 at post mortem that can support this diagnosis.

4 Q. Thank you. Then it says:

5 "Individuals suffering from this condition, due to  
6 their behaviour often come to the attention of  
7 police services and often die during or shortly after  
8 restraint, as was the case here. However, it is not  
9 completely understood why such individuals die."

10 Is this -- when you say it is not completely  
11 understood, can you explain what you mean by that?

12 A. The literature is just not clear as to the actual  
13 mechanisms of death in these cases, so it's not  
14 understood exactly why their heart stops.

15 Q. So is this a situation where medical science has not  
16 provided all of the answers?

17 A. Yes.

18 Q. As to the exact mechanism?

19 A. Yes.

20 Q. Thank you:

21 "A number of studies have been undertaken to look at  
22 the effect of restraint on breathing, but the full  
23 physiological effects of restraint in general is not  
24 fully understood."

25 Can we talk about that element, the possible effect

## Transcript of the Sheku Bayoh Inquiry

1 of restraint on breathing.

2 A. So there have been studies that have been done but  
3 obviously in life -- in a controlled environment,  
4 looking at people if a particular level of restraint is  
5 put to them, to see how it affects their breathing, to  
6 see how it affects their oxygen levels. But as you can  
7 imagine this is a completely false scenario, it's not  
8 what is actually happening when it's happening in real  
9 life and these people are actually dying, so it's  
10 difficult to take kind of any conclusions from these  
11 studies hence why we just don't know because it is -- to  
12 get the actual answers is not studies we would be able  
13 to perform for ethical reasons, obviously.

14 Q. So studies would have -- it would be limited what you  
15 could learn from them because you are not replicating  
16 the exact circumstances that a person finds themselves  
17 in?

18 A. Exactly.

19 Q. So again would that -- would you recommend to the Chair  
20 when he is looking at this that he has to look at the  
21 exact circumstances and the evidence he has heard about  
22 that?

23 A. Absolutely, yes.

24 Q. In terms of the effect of restraint on breathing, any  
25 studies that might be published in the literature will

## Transcript of the Sheku Bayoh Inquiry

1           have limited correlation with the reality that a person  
2           might experience?

3       A.   Exactly, yes.

4       Q.   Then you say:

5                        "This condition is associated with a range of  
6           clinical findings and typically in such cases a high  
7           temperature is documented, however that was not the case  
8           here, with his temperature in hospital noted as being  
9           35.8 [degrees Celsius]."

10      A.   So often in these cases they get a degree of  
11      hyperthermia, so they get a very, very high temperature  
12      and it is one of the things I think that  
13      the psychiatrists look for when they are looking at this  
14      diagnosis.  So~... but in this case I kind of looked  
15      quite hard to find if we had a temperature because  
16      taking someone's temperature is not something that would  
17      be routinely done in this scenario but a temperature was  
18      undertaken in the hospital setting by a nurse, which was  
19      35.8.

20                       But again we have to remember that Mr Bayoh had gone  
21      through a series of resuscitation by that point, to all  
22      intents and purposes was beginning to die, so it is  
23      difficult to know how accurate that temperature would  
24      have been.  Would it have been higher beforehand?  
25      I don't know.  But that is the only temperature that we

## Transcript of the Sheku Bayoh Inquiry

- 1           have to kind of document in the whole scenario.
- 2       Q. I think yesterday when you were talking about narrating  
3       the circumstances, part of your report does mention  
4       a statement you had seen from a nurse who recalled  
5       taking the temperature in hospital?
- 6       A. That is why it's in the background circumstances.
- 7       Q. But as far as I am aware, and I will be corrected if  
8       I'm wrong, there is no information available to the  
9       Chair about the temperature of Mr Bayoh at  
10      Hayfield Road?
- 11      A. No. No. I went through it, all of the  
12      information I was given, and that was the only  
13      temperature that I could find.
- 14      Q. Thank you. The Chair has heard evidence last year from  
15      people talking about the weather, and the weather  
16      conditions on that day at the time Mr Bayoh was in  
17      Hayfield Road, and the fact he was wearing a T-shirt,  
18      a short-sleeved T-shirt, others were wearing further  
19      clothing. It wasn't necessarily the nicest May day.  
20      Would you recommend to the Chair that he bear that in  
21      mind when he is considering temperature or the  
22      significance of temperature to the overall situation?
- 23      A. I have absolutely no knowledge if that would mean that  
24      his temperature was higher just because he wasn't  
25      wearing the same clothes as anybody else, pathologically

## Transcript of the Sheku Bayoh Inquiry

1           that is not something I could comment on.

2           Q. All right. Thank you. So those were the -- as  
3           I understand it, those were the areas where you looked  
4           for signs in the post mortem and investigated them,  
5           considered them and took the view that they didn't have  
6           anything to do with the actual pathological cause of  
7           death?

8           A. Yes.

9           Q. Is there anything that I have missed?

10          A. I don't think so, no.

11          Q. Let's move on then to look at the signs that you found  
12          which I think you concluded were indicative or factors  
13          that could play a part in the cause of death. I'd like  
14          to begin by looking at your paragraphs on toxicology, if  
15          I may. So that is page 15. If we can move down to  
16          paragraph 4 on that page. It starts with toxicology and  
17          we will look at that and the next paragraph, the final  
18          paragraph. Here you say:

19                 "Toxicology revealed in hospital blood, post mortem  
20                 blood and post mortem urine the presence of MDMA~... MDA  
21                 and Alpha-PVP."

22                 We spoke about this yesterday, I am interested in  
23                 you explaining MDA for us today if possible?

24          A. So MDA is a metabolite of MDMA and can also exist as  
25          a drug on its own, so it can be a separate drug to MDMA.



## Transcript of the Sheku Bayoh Inquiry

1           But the levels present here, given the level of MDA was  
2           much lower, would suggest it is probably a metabolite of  
3           the ecstasy as opposed to being a second drug. So we  
4           have -- I think one of the main drugs that have been  
5           found is MDMA, which the kind of street name for that  
6           would be ecstasy or what the public would be aware of as  
7           ecstasy.

8           Q. You helpfully detailed all of the specific measurements  
9           and drugs on pages 11 and 12 of your report.

10          A. Yes.

11          Q. That was taken from the toxicology report that you had  
12          been provided with?

13          A. Yes.

14          Q. The other thing that I noticed in your own report is you  
15          mentioned some of the blood was preserved and some of it  
16          was unpreserved. I wondered if you could explain to the  
17          Chair the distinction between those two.

18          A. Preserved blood is taken in a separate sample pot that  
19          has a preservative in it, and it is basically used for  
20          mainly alcohol because it is produced after blood  
21          because it stops -- it reduces further production of the  
22          drug. It is also useful in other drugs like cocaine and  
23          digoxin because again it can stop further production of  
24          the drug or breakdown of the drug after the person is  
25          dead.

## Transcript of the Sheku Bayoh Inquiry

1           So we use it specifically for certain drugs, so that  
2           the information that we're getting in terms of levels  
3           can be as accurate as possible, because that, as  
4           I explained yesterday, can change after death with the  
5           breakdown in the body and the post mortem  
6           redistribution.

7           Q. So on page 11 and 12 of your report you have highlighted  
8           what the results were from the preserved blood and the  
9           unpreserved blood?

10          A. Yes, and specific things will be checked for in the  
11          preserved blood and then specific things will be checked  
12          for in the non-preserved blood.

13          Q. So can we look at page 11 for the moment and just the  
14          first two entries preserved blood we see the Alpha-PVP  
15          at 0.31 and then we see the unpreserved blood has MDMA  
16          and Alpha-PVP as well and at different levels. And the  
17          MDA. Can you explain why preserved blood would only  
18          find the Alpha-PVP but the unpreserved would have all  
19          three present?

20          A. It's a very small sample size that we give for preserved  
21          blood, it's just a few millilitres, whereas unpreserved  
22          blood we normally give as much as we possibly can so it  
23          can be kind of 10 to 20ml, so they would have looked for  
24          the parent drug in the preserved because that is  
25          the important thing, the metabolites are not as

## Transcript of the Sheku Bayoh Inquiry

1           important, it's important to know exactly if the parent  
2           drug is present and at what level. So they would have  
3           looked in the preserved sample for that in particular  
4           and then rechecked it in the unpreserved as a comparison  
5           and done the metabolites in the unpreserved. So it's  
6           the amount of sample that is available and the  
7           importance of the -- and what kind of -- what needs to  
8           be done first.

9           Q. Right. Then with the urine sample, again that is  
10          preserved and unpreserved. Is that the same position  
11          that the preserved contains a preservative within it?

12         A. Yes, uh-huh. In this case I have sent two lots of  
13          urine. I would only normally send one preserved urine  
14          sample, I wouldn't normally send an unpreserved but the  
15          reason the extra urine was sent was because we were  
16          looking for steroids to check for nandrolone for the  
17          anabolic steroids. But yes, it's exactly the same. The  
18          urine sample would have gone in a very small preserved  
19          bottle which has the preservative in it and then there  
20          would have been a larger amount sent separately.

21         Q. What do we see present in the unpreserved urine?

22         A. So we have the MDMA, which is the ecstasy, and then you  
23          have the metabolite so it's -- and kind of other  
24          metabolites of that.

25         Q. So in terms of the urine which was preserved, it only

## Transcript of the Sheku Bayoh Inquiry

- 1           came up with Alpha-PVP but again was that to do with the  
2           amount, the sample?
- 3        A. That is probably all that would have been checked for in  
4           that urine.
- 5        Q. Then we see three hospital bloods samples listed.  
6           I think you said in the earlier part of the toxicology  
7           section there were four hospital blood samples.
- 8        A. So one of them wouldn't have been analysed, they don't  
9           analyse all of them. Not all of them are of a quality  
10          that can be analysed or they have enough volume from the  
11          other samples that they don't require to analyse. That  
12          would be a question for the toxicologists.
- 13       Q. Again, we see here the presence of MDMA, the metabolite  
14          MDA and Alpha-PVP?
- 15       A. Yes.
- 16       Q. And all other analyses were negative. I think you said  
17          yesterday there were a lot of other tests done?
- 18       A. Yes.
- 19       Q. But you would only mention in your report what was  
20          actually positive?
- 21       A. Yes.
- 22       Q. Then if we can move down that page, please. You talk  
23          about the urine sample and say they showed the presence  
24          of nandrolone and metabolites consistent with the recent  
25          admin of anabolic steroid nandrolone, and I think you

## Transcript of the Sheku Bayoh Inquiry

1           gave evidence about that yesterday?

2           A. Yes.

3           Q. Thank you very much. You have mentioned MDMA, you have  
4           mentioned the Alpha-PVP. Can you help the Chair  
5           understand the impact of these drugs on a person, or is  
6           that more for the toxicologists?

7           A. No, I can give certainly an explanation of how people  
8           may behave clinically and certainly how they can cause  
9           someone's death. That would be probably more my remit  
10          than the toxicologists' remit.

11          Q. Would you be able to help us with that please?

12          A. They are both stimulant drugs, and by stimulant drugs  
13          I mean they can have an effect on the cardiovascular  
14          system so they can cause an increase in heart rate and  
15          an increase in blood pressure and they can also cause  
16          arrhythmias. Yesterday I was talking about the  
17          conduction system of the heart and how the conduction  
18          system involves the beating of the heart, so they can  
19          affect that system, and they can result in a cardiac  
20          arrhythmia that is not kind of conducive to life,  
21          basically the heart can't beat properly and the heart  
22          then stops, and causes a sudden cardiac arrest. So any  
23          stimulant drugs, that is one of the kind of extreme  
24          complications of that.

25                 The Alpha-PVP is a drug that can cause alterations

## Transcript of the Sheku Bayoh Inquiry

1           in someone's behaviour. It can cause euphoria, it can  
2           cause agitation, hallucinations, delusions, so often we  
3           get a history of people behaving very bizarrely and  
4           completely out of character beforehand, and that is  
5           the type of drug that they tend to have on board. But  
6           ultimately both drugs have a similar mechanism of action  
7           in that they both stimulate the heart in adverse ways  
8           and can cause the heart to stop in a sudden cardiac  
9           arrest.

10          Q. Would they both cause the heart rate to increase?

11          A. They can do, yes.

12          Q. Would they both cause the blood pressure to increase?

13          A. Yes.

14          Q. And both can cause an arrhythmia?

15          A. Yes.

16          Q. Would it be the arrhythmia that would cause the sudden  
17           death, where the heart would be unable to pump oxygen  
18           around the body?

19          A. Exactly, yes.

20          Q. And ultimately if that -- if the heart stops, that will  
21           be the point at which they die?

22          A. They are in cardiac arrest at that point, yes.

23          Q. That is the impact on the heart. Can you explain to us  
24           what the impact on your respiratory system is, if there  
25           is one?

## Transcript of the Sheku Bayoh Inquiry

1           A. With these drugs it is difficult to be specific about  
2           the respiratory system. There are other drugs that can  
3           cause a degree of depression of breathing, they are more  
4           drugs like heroin and codeine and things like that,  
5           whereas these two types of drugs seem to be more  
6           stimulant-related. Although, if you are -- if your  
7           heart is not working properly, if your blood pressure is  
8           going up, if your heart rate is going up, then  
9           everything is having to work harder, so that would have  
10          a knock-on effect with your lungs having to work harder  
11          and a degree of kind of damage to the lungs that could  
12          present adversely.

13          Q. If your heart is working harder, and what is the -- what  
14          are the visible signs on your respiratory system, if  
15          any?

16          A. You could be a bit more breathless. There may be no  
17          signs at all. You could be a bit breathless. That is  
18          probably the main thing. You could have some pains in  
19          your chest potentially, from both the heart problems and  
20          the kind of lung problems.

21          Q. When you say these drugs can have a -- can they cause  
22          harm to the respiratory system; can that damage or that  
23          harm be seen by a pathologist?

24          A. No. It's all -- kind of all very acutely so there  
25          wouldn't be anything to see down the microscope or

## Transcript of the Sheku Bayoh Inquiry

1           grossly. You can -- the congestion and oedema that  
2           I spoke about yesterday is another possible sign of the  
3           lungs but again, as I said yesterday, in the scenario  
4           here there are so many different things that could have  
5           fed into that congestion and oedema that it is  
6           impossible to be specific as to what exactly has caused  
7           that.

8           Q. So again, another area where a forensic pathologist such  
9           as yourself cannot explain why those lungs or how those  
10          lungs might be affected by consumption of these  
11          stimulant drugs?

12          A. Yes.

13          Q. Returning to your report, please, on page 15. We were  
14          looking at the toxicology. You've talked about the  
15          metabolites of MDMA:

16                 "MDA is also a metabolite ... but can be encountered  
17                 on its own~..."

18                 I think you have just told us that:

19                 "... or as a constituent of ecstasy tablets. If its  
20                 level in blood is lower than that of MDMA, as was the  
21                 case here, it is likely to be present as a metabolite of  
22                 MDMA, rather than a separate drug on its own."

23                 Is that what you were saying earlier?

24          A. Yes.

25          Q. Then it says, final paragraph on this page:



## Transcript of the Sheku Bayoh Inquiry

1           "MDMA is a stimulant drug that can result in sudden  
2 death from a fatal cardiac arrhythmia and/or a seizure,  
3 albeit there was no history of a seizure in this case."

4           Is that something you would be aware of from the  
5 circumstances or something you could find in the  
6 post mortem?

7       A. No, it's something that I would have to be made aware of  
8 from the circumstances. You can't diagnose a seizure at  
9 post mortem.

10       Q. But nothing that you were able to find from the  
11 circumstances and your consideration of the medical  
12 records to indicate there is any problem that way?

13       A. No.

14       Q. "Alpha-PVP is a substituted cathinone and the Database  
15 on New Drugs reports a number of health risks associated  
16 with this drug including neuropsychic (euphoria,  
17 psychomotor agitation, hallucinations/delusions,  
18 seizure/tremor and paranoia)~..."

19           I wonder if you could explain what those are?

20       A. So these are how people may present if they take this  
21 drug, so euphoria is a -- I suppose they appear kind of  
22 high, not quite themselves, they can be very, very  
23 agitated, very paranoid to people around them, they can  
24 hallucinate, so they can see things or hear voices that  
25 are not necessarily there. And they can also have

## Transcript of the Sheku Bayoh Inquiry

1 tremors, so kind of shaking and things like that. So  
2 these are all I suppose clinical symptoms that people  
3 that take these drugs can present with.

4 Q. Then you mention:

5 "... cardiovascular (hypertension, tachycardia).

6 What does that mean?

7 A. Hypertension is high blood pressure and tachycardia is  
8 a high pulse.

9 Q. And neither of those would be apparent to you on  
10 a post mortem?

11 A. No. No.

12 Q. "This may explain his behaviour prior to his death.  
13 With regards to this drug there is limited information  
14 about acute intoxication and fatal cases but its effects  
15 appear similar to that seen in acute cathinone  
16 toxicity."

17 Is that essentially what you have been talking  
18 about, that this can cause a sudden death because of the  
19 toxicity of the drugs themselves?

20 A. Yes.

21 Q. Then just finishing off that paragraph:

22 "Cathinones have stimulant effects similar to  
23 amphetamine and as such could also result in a fatal  
24 cardiac arrhythmia."

25 Is that what you mentioned earlier?

## Transcript of the Sheku Bayoh Inquiry

1 A. Yes.

2 MS GRAHAME: I am conscious it is 11.30 am.

3 LORD BRACADALE: Very well. We will have a 20-minute break  
4 at that point.

5 (11.30 am)

6 (A short break)

7 (11.57 am)

8 MS GRAHAME: Thank you, let's go back to page 16, if I may,  
9 we have been talking before the break about things that  
10 you were able to find and positive results from your  
11 investigations.

12 We had been talking about toxicology and just to  
13 complete this section, in paragraph 2 of page 16 you  
14 say:

15 "The toxicology also revealed in the urine  
16 nandrolone and metabolites~..."

17 And that was:

18 "... consistent with recent administration of  
19 anabolic steroid. Given there was no evidence of heart  
20 disease, this drug is unlikely to have played a role in  
21 death here."

22 So again, something else you have been able to  
23 exclude as part of the overall picture?

24 A. Yes.

25 Q. Then moving on to page 17, if I may, I would like to

## Transcript of the Sheku Bayoh Inquiry

1           look at another factor and you consider here the impact  
2           of restraint. So the restraint of Mr Bayoh by the  
3           police officers.

4           If we look at paragraph 1 on page 17 it says:

5           "In terms of the history of restraint here, Mr Bayoh  
6           was reportedly face down with his hands cuffed in front  
7           of him (this is supported by the presence of injury 16),  
8           his legs were tied around the knees and ankles and at  
9           least four officers were restraining him."

10          Is that a summary of your understanding of the  
11          circumstances?

12          A. Yes.

13          Q. Then you say:

14          "Post mortem examination showed the presence of  
15          petechial haemorrhages~..."

16          We spoke about those yesterday:

17          "... within the eyes and whilst these are not  
18          specific and can be seen in someone who has been  
19          resuscitated, they could indicate a degree of asphyxia."

20          So am I correct in saying your view was that  
21          the presence of those petechial haemorrhages that you  
22          described in evidence yesterday could be indicative of  
23          a degree of asphyxia?

24          A. Yes.

25          Q. And:

## Transcript of the Sheku Bayoh Inquiry

1            "In this case, given the reported circumstances,  
2            possible causes of asphyxia would include positional  
3            (the position of the body interferes with breathing) and  
4            mechanical (something impeding the body's ability to use  
5            muscles for breathing)."

6            I think you explained those yesterday in evidence.

7            A. Yes.

8            Q. I would like to look at the issue of restraint in  
9            a little bit more detail. When the Chair is coming to  
10           consider the importance or the impact of restraint on  
11           Mr Bayoh and the circumstances that existed at the  
12           scene, I'd like to be clear exactly what factors you  
13           have considered significant to your own conclusions.

14           I think you mention -- on page 15 of your report, if  
15           we look at paragraph 3 that there are a number of  
16           blunt-force injuries. You've detailed a number of these  
17           here. You've given evidence in detail yesterday about  
18           all the injuries that you found, both externally and  
19           internally.

20           A. Uh-huh.

21           Q. And the Chair can consider that in due course. But  
22           you've said that there were injuries -- a number of  
23           injuries you detail here: abrasions, lacerations,  
24           I don't want to go through them all again, but you also  
25           say there was the internal examination that revealed

## Transcript of the Sheku Bayoh Inquiry

1 a fracture to the left first rib, we talked about that  
2 yesterday and this could have been sustained whilst he  
3 was being restrained. So that is one of the possible  
4 mechanisms whereby that injury could have resulted in  
5 Mr Bayoh ...?

6 A. Yes.

7 Q. Albeit the possibility of it occurring during  
8 resuscitation cannot be completely excluded?

9 A. It would be very, very rare but I couldn't say  
10 definitively 100% that it has not been caused by  
11 resuscitation.

12 Q. I think in your Inquiry statement you say it would be  
13 rare if CPR and the attempts at resuscitation had caused  
14 an injury to the first left rib?

15 A. Especially an isolated injury with no injuries elsewhere  
16 that could be related to resuscitation.

17 Q. I think yesterday you said there were no injuries to the  
18 second rib?

19 A. No.

20 Q. And you also said on the trunk, including that area,  
21 there was no external bruising or injuries or anything  
22 of that sort?

23 A. No.

24 Q. No lacerations or anything?

25 A. No.

## Transcript of the Sheku Bayoh Inquiry

- 1 Q. So the injury, the fracture to the first left rib is  
2 underneath the skin with no surrounding external  
3 injuries associated with it?
- 4 A. Yes.
- 5 Q. "Notably, in keeping with the history of him being  
6 restrained there was an injury to the left wrist~..."  
7 And you detail the specific injury:  
8 "... with corresponding bruising into the  
9 subcutaneous tissue."  
10 So is that an injury that we talked about yesterday,  
11 injuries to the wrist, I think you said they were  
12 consistent with handcuffs?
- 13 A. Yes.
- 14 Q. So if handcuffs had been applied during the restraint,  
15 those injuries would be consistent with that?
- 16 A. Yes.
- 17 Q. And I think you also mentioned yesterday injuries that  
18 would be consistent perhaps with leg restraints, or  
19 baton strikes?
- 20 A. Yes.
- 21 Q. And specifically I think you talked about injuries to  
22 the shins could be more consistent with baton strikes,  
23 I think you said yesterday?
- 24 A. Yes.
- 25 Q. So again, all of those injuries would be consistent with

## Transcript of the Sheku Bayoh Inquiry

1 a restraint having been carried out?

2 A. Yes.

3 Q. And I think yesterday you said also the struggling  
4 against the restraint as well?

5 A. Yes.

6 Q. Then yesterday you talked about injuries which were  
7 perhaps consistent with skin scraping along the ground?

8 A. Yes.

9 Q. Some were consistent with over clothing -- without  
10 clothing being present on the lower parts of the arms,  
11 some underneath a T-shirt would still be consistent, the  
12 one on the left trunk?

13 A. Yes.

14 Q. Again, those injuries which you detailed yesterday,  
15 again were they consistent with a restraint having been  
16 carried out?

17 A. Consistent with him being on the ground. I don't think  
18 they are related to restraint specifically but certainly  
19 him being on the ground.

20 Q. And consistent with him struggling on the ground?

21 A. Yes.

22 Q. And consistent with the circumstances that you're aware  
23 of?

24 A. Yes.

25 Q. As happened in Hayfield Road.



## Transcript of the Sheku Bayoh Inquiry

- 1 A. Yes.
- 2 Q. Then there was some description by you yesterday about  
3 the injury on the left forehead. Was that also  
4 potentially an injury consistent with the circumstances  
5 that you know about, as occurred in Hayfield Road?
- 6 A. Yes.
- 7 Q. And also use of batons, consistent with blunt-force  
8 injury?
- 9 A. Potentially, yes.
- 10 Q. So you detail those there, you talk about:  
11 "Internal examination of the head and face showed  
12 several areas of bruising in keeping with blunt-force  
13 impacts to these areas (and could be in keeping with  
14 being sustained as a consequence of baton use)~..."
- 15 A. Yes.
- 16 Q. You still agree with that?
- 17 A. Yes.
- 18 Q. "... but there was no evidence of fracturing of the  
19 skull or facial bones."
- 20 A. Yes.
- 21 Q. You talked yesterday about the level of force and how it  
22 might be indicative, if bones are fractured, of a more  
23 severe level of force?
- 24 A. Yes.
- 25 Q. If bones are not fractured is that indicative of a less

## Transcript of the Sheku Bayoh Inquiry

1           severe level of force?

2           A. Routinely, yes.

3           Q. Then you say:

4                        "Neuropathology was undertaken which showed changes  
5                        consistent with evolving global ischaemic brain injury  
6                        secondary to cardiac arrest with resuscitation and short  
7                        survival period but no other significant  
8                        abnormality~..."

9                        Was that the evidence you gave yesterday about the  
10                       neuropathology results and the investigations that had  
11                       been carried out?

12          A. Yes.

13          Q. Again, they would be consistent with the circumstances  
14               as you understand them as to what happened at  
15               Hayfield Road?

16          A. Yes.

17          Q. Then -- yes, we dealt with the final sentence. So those  
18               are all the injuries, those appear consistent with your  
19               understanding of the events at Hayfield Road. Can I ask  
20               you about some other aspects of evidence that we've  
21               heard and you can explain to the Chair if they would  
22               also be significant in the context of this -- or  
23               consistent with a restraint and the events at  
24               Hayfield Road or not.

25                       Signs that perhaps force had been applied on to the

## Transcript of the Sheku Bayoh Inquiry

- 1           back of Mr Bayoh, so we talked yesterday about you  
2           examining the back and I'm interested were there any  
3           factors that you could say were relevant to a question  
4           of force being applied to his back?
- 5        A. I think on examination of the back there was one area of  
6           haemorrhage over the left upper back which is indicative  
7           of a degree of blunt-force trauma. There was nothing  
8           externally on the skin that was obvious and just one  
9           area internally, so there certainly wasn't anything kind  
10          of pathologically that would signify a severe degree of  
11          force being applied to the back from those findings.
- 12       Q. What about weight being applied to his back, the weight  
13          of someone perhaps leaning or lying across his back; any  
14          signs of that?
- 15       A. If that had occurred it hadn't occurred in any  
16          significant injuries to confirm that.
- 17       Q. We may have heard evidence about Mr Bayoh attempting  
18          some sort of press-up manoeuvre to try and remove  
19          officers and the weight of officers off his back. Any  
20          signs of that in the post mortem that -- or signs that  
21          could be consistent with that having happened?
- 22       A. Not from the findings. But you wouldn't necessarily  
23          need to see anything for that to have happened.
- 24       Q. Anything that you could identify that may be consistent  
25          with an officer rolling down the legs of Mr Bayoh,

## Transcript of the Sheku Bayoh Inquiry

1 rolling -- turning from the upper thigh or above  
2 the knee area down to the ankle area with a view to  
3 stopping movement of his legs and helping with the  
4 application of leg straps? Anything that you could see  
5 that would help in that?

6 A. No.

7 Q. Is the -- the Chair has also heard evidence about  
8 the duration of these events. He has heard evidence  
9 about the Airwave transmissions that were being made at  
10 certain moments in time and he has looked at CCTV  
11 showing the police arriving and the period of time  
12 before Mr Bayoh was on the ground. Is the duration of  
13 any significance to your role as a forensic pathologist?

14 A. I think knowing about the duration, knowing as much  
15 about the circumstances is important because the longer  
16 it is happening and the longer he may be in a particular  
17 position, the more likely that there might be an adverse  
18 outcome. So it is important to know how long it's all  
19 been happening for and what has been happening in that  
20 time.

21 Q. Are there any cut-off points that you are aware of that  
22 make things more dangerous or less dangerous?

23 A. Not specifically.

24 Q. Nothing you know of. Thank you. You've mentioned a lot  
25 of these factors, can I ask you again about the

## Transcript of the Sheku Bayoh Inquiry

1           petechial haemorrhages, they are consistent with the  
2           circumstances that --

3       A.   Yes.

4       Q.   -- you are aware of?

5       A.   They can be seen in deaths that are related to asphyxia  
6           but as I said yesterday there's a number of other  
7           reasons that they can be seen as well, so they are not  
8           specific to those types of deaths.

9       Q.   Would you -- in relation to helping the Chair, would you  
10           say that he shouldn't look at anything in isolation but  
11           consider all of the evidence available?

12      A.   Absolutely, yes.

13      Q.   So your evidence is -- and your findings, that's part of  
14           the whole picture for the Chair to put together?

15      A.   Yes.

16      Q.   Is there anything I have missed in relation to the  
17           restraint that you think is an important factor that the  
18           Chair should be aware of, that I've not mentioned to  
19           you?

20      A.   No, I think the restraint is -- is there and is in the  
21           cause of death because of the information that  
22           I had been given in the lead-up to Mr Bayoh's death in  
23           addition to the findings at post mortem. You often, in  
24           such cases of restraint, you may not find a huge amount  
25           at post mortem examination. Petechial haemorrhages are

## Transcript of the Sheku Bayoh Inquiry

1           one of things that you can see, depending on the  
2           mechanism of constraint. With positional asphyxia you  
3           may see a very congested kind of bloated face. That is  
4           difficult in this case because of the colour of  
5           Mr Bayoh's skin as well. So my consideration of the  
6           restraint and the importance of it in this case is very  
7           much based on all of the information I have been given  
8           in the lead-up to his cardiac arrest in addition to what  
9           I have been able to identify or not identify at the time  
10          of the post mortem.

11         Q. From everything you have seen and all the results and  
12           tests you have done was there anything that caused you  
13           to think: I've got this wrong?

14         A. No, no.

15         Q. Anything missing that absolutely should have been there  
16           that you think: if that isn't there, I must be getting  
17           this wrong?

18         A. No, no, I think I had all of the information I needed.

19         Q. Thank you. You've been asked a number of questions as  
20           part of the Inquiry statement process but before I move  
21           on to that I just want to look at the final section of  
22           your conclusions on page 17.

23                 These are your conclusions:

24                 "Taking everything into consideration, death here  
25                 was sudden in nature. In summary, there was no evidence

## Transcript of the Sheku Bayoh Inquiry

1 of gross or histological natural disease that would  
2 account for death. Toxicology revealed MDMA and  
3 Alpha-PVP and these drugs could potentially have caused  
4 sudden death at any time due to a fatal cardiac  
5 arrhythmia. That said, it is recognised that restraint  
6 in itself can be a cause or contributing factor in some  
7 deaths and given the circumstances, in that this man was  
8 restrained at the time of his respiratory arrest and  
9 post mortem examination showed petechial haemorrhages  
10 that may represent a degree of asphyxia, it cannot be  
11 completely excluded that restraint has also had a role  
12 to play in death here."

13 So you are not excluding the fact that restraint  
14 could have had a role to play:

15 "Overall it is not possible to be sure what has been  
16 the most significant factor in death here and as such  
17 the cause of death is best regarded as being: sudden  
18 death in a man intoxicated by MDMA ... and Alpha-PVP,  
19 whilst being restrained.

20 "There were no other significant findings.

21 "The cause of death should therefore be amended  
22 to ..."

23 And that is amended from your initial report which  
24 was "unascertained"?

25 A. Yes.

## Transcript of the Sheku Bayoh Inquiry

1 Q. To:

2 "1a. Sudden death in a man intoxicated by MDMA~...  
3 and Alpha-PVP whilst being restrained."

4 A. Yes.

5 Q. That was your conclusion, that was your certification of  
6 the cause of death, your explanation from all of the  
7 work that you did --

8 A. Yes.

9 Q. -- in investigating Mr Bayoh's death.

10 Now, I think subsequent to this in your Inquiry  
11 statement you were asked -- I think it was suggested to  
12 you that another expert had suggested perhaps the  
13 struggle should not be excluded from that.

14 A. Absolutely, yes.

15 Q. That the struggle as well as the restraint were both  
16 significant.

17 A. Yes.

18 Q. Do you want to comment on that now?

19 A. So during these types of struggles with how the deceased  
20 may have behaved and moved, they would have been using  
21 a great degree of kind of muscle strength, and whilst  
22 doing that it kind of -- it is such intensity you can  
23 get a breakdown of proteins in the muscle that produces  
24 acids, and you can get something that we call  
25 an acidosis, so you get acids circulating in the blood



## Transcript of the Sheku Bayoh Inquiry

1 stream. Those acids, because of their chemical  
2 structure, can cause irritation of the heart and can  
3 irritate the conduction system I was talking about and  
4 can also lead to cardiac arrhythmias and cardiac arrest.

5 So again, it is something that -- it's impossible to  
6 prove pathologically, I don't see anything at the  
7 post mortem to confirm this. But again, it is taken in  
8 consideration with the circumstances that are described,  
9 and that certainly is -- if I was revisiting and I have  
10 had cases subsequently to this case in recent years  
11 where I have put "whilst struggling", or "being  
12 restrained", into the actual cause of death because  
13 I think the struggle is a major part of it as well.

14 Q. So is that a sort of integral part, being restrained and  
15 struggling against the restraint?

16 A. It is something that definitely has to be considered as  
17 being important in the whole scenario.

18 Q. Thank you. In terms -- you have talked about  
19 examination. Is there any test that can be carried out  
20 to show if there's acidosis or acid in the system?

21 A. There are some tests we can do pathologically for  
22 specific acids and we did do in this case acetone and  
23 beta-hydroxybutyrate, which are both acids that weren't  
24 there. But the acid that tends to be seen in these  
25 cases is a lactic acid and that is not something that we

## Transcript of the Sheku Bayoh Inquiry

1           can test for at post mortem. It is the acid that is  
2           produced if you are kind of working out in the gym, if  
3           you are lifting weights and you get pain in your  
4           muscles, that is your lactic acid being produced and  
5           that tends to be the acid that is produced in these sort  
6           of scenarios when it's the muscle that is breaking down.

7           Q. How quickly does lactic acid leave the system or leave  
8           no trace, or is it just simply that you don't -- medical  
9           science or science hasn't quite --

10          A. I don't know how -- I wouldn't be able to answer about  
11          how quickly it leaves the system but from a post mortem  
12          point of view I don't have a lab that I could get to  
13          analyse for lactic acid.

14          Q. So these are tests that simply cannot be done by you?

15          A. Yes.

16          Q. Thank you. But ultimately if there is a build-up of  
17          that acid it could irritate the heart and the conduction  
18          system?

19          A. Yes.

20          Q. Thank you. You've mentioned -- if we can move back down  
21          the page slightly, you say:

22                 "Overall it's not possible to be sure what has been  
23                 the most significant factor in death here~..."

24                 For the public listening, is there a way you can  
25                 attribute percentages to different things, such as MDMA

## Transcript of the Sheku Bayoh Inquiry

1           was 20% the cause of death and Alpha-PVP was 10%? Can  
2           you do that sort of assessment?

3           A. No. No, I can't. I can't with any degree of certainty  
4           say exactly what has been the more significant factor.  
5           Certainly not putting percentages on anything, it is  
6           impossible. The drugs were both there, they both have  
7           a similar mechanism of action so regardless they both  
8           pathologically would have been important as each other.

9           Q. When you say it is not possible to be sure what has been  
10          the most significant factor, how as a pathologist do you  
11          assess what factors become relevant to your explanation  
12          for the cause of death, and which you ignore and say are  
13          not relevant? How do you go through that process?

14          A. I think the easiest way to do it is look at them  
15          individually. So if I had a case where the only thing  
16          I was finding was ecstasy, then that would be my cause  
17          of death. If I had a case where the only thing I was  
18          finding was Alpha-PVP that would be my cause of death.  
19          If I had a case where I was given a particular scenario  
20          of restraint and had all the circumstances ticking the  
21          boxes that required but the post mortem examination  
22          revealed nothing else, no other obvious cause of death  
23          no other toxicological cause of death or natural cause  
24          of death, then that would be my cause of death.

25                 So that is how I tend to look at it: if it exists on

## Transcript of the Sheku Bayoh Inquiry

1           its own, could it have been responsible for this  
2           person's death? And in this case all of these  
3           individual factors could have, if they just existed on  
4           their own with the correct set of circumstances. So  
5           that is how I have come to that conclusion.

6           Q. In this situation there are a number of different  
7           circumstances that could combine to cause death. That  
8           is certainly what you have concluded.

9           A. Exactly.

10          Q. So in that case do you even endeavour or attempt to  
11          distinguish between the causes of death, the factors  
12          here? Do you try and assess the difference between the  
13          level the drugs made and the level the restraint made?

14          A. I do try but certainly in this case there is nothing in  
15          all of the information I have and what I have found at  
16          post mortem with all the ancillary investigations to  
17          separate out these different factors so they are all in  
18          the primary cause of death hence why it's given as  
19          a narrative explaining them all.

20          Q. So that you mentioned the important parts as far as you  
21          are concerned?

22          A. Exactly.

23          Q. Of course including what you now say is the struggle?

24          A. Yes, yes.

25          Q. We may hear other evidence and the Chair may hear

## Transcript of the Sheku Bayoh Inquiry

1           submissions about things that are de minimis, a Latin  
2           phrase. Have you got an awareness of de minimis and the  
3           fact it's something so trivial so as not to take into  
4           account?

5           A. Yes.

6           Q. Do you dismiss anything that you would class as  
7           de minimis?

8           A. I would do, I would always discuss it if I have that  
9           information, but with the caveat that it has not played  
10          a significant role in death. So for example natural  
11          disease in this case, I would discuss it but there is  
12          nothing to suggest that there is anything there that  
13          would have been significant. If there had have been it  
14          may have been something very, very minor that would have  
15          been possibly in part 2 of the cause of death as not  
16          significant. But there wasn't in this case. So we  
17          would consider everything but have to exclude certain  
18          things depending on the information.

19          Q. So in terms of your own conclusions, the cause of death  
20          was -- the explanation for Mr Bayoh's sudden death was  
21          due to both the drugs, the intoxication from the drugs  
22          that you have listed, and the fact he was being  
23          restrained at the time?

24          A. Yes.

25          Q. Thank you. I would like to move on to what happened

## Transcript of the Sheku Bayoh Inquiry

1 after your final report because I understand there were  
2 further investigations carried out. Could we look at  
3 a supplementary report that you prepared. It's  
4 COPFS 00040. You will see here it says, "Supplementary  
5 report", and this was on 3 October 2017. If we can just  
6 move down the page, please. We will see again it  
7 relates to Mr Bayoh and it's exactly the same sort of  
8 front sheet if you like as you had before. If we can  
9 move on to the next page. We see it says:

10 "Following a request, post mortem blood was  
11 submitted for testing for sickle cell disease."

12 So was this a separate later request that was  
13 made --

14 A. It was.

15 Q. -- to have this checked?

16 A. Yes.

17 Q. And it -- I wonder if you could explain what sickle cell  
18 disease is?

19 A. It's a blood disorder where you get abnormal shape of  
20 the red blood cells, which reduces the blood cells'  
21 capacity to carry oxygen. So people with this disease  
22 can have problems with their blood kind of matting  
23 together and can have pain and problems with -- kind of  
24 chest pain and breathing and things like that and can  
25 become hypoxic with low oxygen because the blood is not

## Transcript of the Sheku Bayoh Inquiry

1           circulating properly in their body.

2           Q. I think earlier you said you had looked at medical  
3           records and had there been any reference at all to  
4           anything like that in the medical records?

5           A. No.

6           Q. So this was requested, and was further post mortem blood  
7           taken at that stage or was it the original?

8           A. It was the original --

9           Q. The original?

10          A. -- that had been stored.

11          Q. Stored. Then it says:

12                        "This confirmed Mr Bayoh was a carrier of  
13           sickle cell disease and therefore had the trait but not  
14           the disease."

15          A. Yes.

16          Q. Would you explain that for us, please?

17          A. So carriers of sickle cell disease can go through life  
18           with no problems whatsoever and are often undiagnosed,  
19           and it doesn't cause them any ill harm, it doesn't cause  
20           them any problems. In specific situations, which are  
21           normally quite extreme situations, things like a member  
22           of the army is on -- doing an expedition in the desert  
23           so they are doing lots of very, very tough exercise in  
24           very high temperatures, in that sort of scenario where  
25           they really are requiring a really high oxygen capacity,

## Transcript of the Sheku Bayoh Inquiry

1           they don't -- the trait becomes apparent in that the  
2           blood cells may begin to sickle, so cause this abnormal  
3           shape which affects the oxygen carrying capacity and  
4           those people can become quite ill and can actually die.

5           So, whereas the disease is someone who has in very  
6           kind of little scenarios can be very unwell and these  
7           people often present repeatedly with pain and being  
8           unwell and require regular medical management, so these  
9           people it affects their life and it won't go  
10          undiagnosed, it will probably be diagnosed reasonably  
11          early in life because they will have clinical symptoms  
12          and will present to medical staff. Whereas with the  
13          actual trait it doesn't tend to present unless these  
14          people are put in an extreme situation that affects  
15          their oxygen carrying capacity in an extreme way.

16        Q.   So you have already said there were no signs in the  
17           medical records of anything resembling sickle cell  
18           disease. When you are thinking about an extreme  
19           situation that would affect oxygen carrying capacity, so  
20           for someone who has the trait, the sickle cell trait,  
21           can you give us another example of what type of extreme  
22           situation you mean. For someone who isn't in the army  
23           working in the desert, what would an extreme situation  
24           be?

25        A.   Someone who has climbed a mountain, so used a great deal



## Transcript of the Sheku Bayoh Inquiry

1 of energy to climb that mountain, got to the top and as  
2 you know at altitude the oxygen levels are much lower  
3 than when you are not at altitude so your requirements  
4 increase but they wouldn't be able to substitute for  
5 that, they wouldn't be able to change their physiology  
6 for that, so that would be another extreme situation.

7 Q. How quickly can sickling occur?

8 A. Again, I don't know from a medical point of view.

9 I would have to refer to a kind of haematology expert.

10 It's not within my --

11 Q. We may hear other evidence about this that we can  
12 explore. From your awareness is it something that you  
13 can see -- if the sickling has occurred, can  
14 a pathologist identify that?

15 A. It's not something I have ever seen as a pathologist.

16 It is not -- I have never come across any patients with  
17 sickle cell trait or disease. It's one of those things  
18 that it's very, very difficult to diagnose at  
19 post mortem because after someone dies or even prior to  
20 them dying, the body will have a degree of hypoxia and  
21 you can see sickle cells in a post mortem setting of  
22 people without the trait or without the disease. So  
23 it's very difficult to know how important it is because  
24 of the post mortem changes that you may see anyway. But  
25 my practice, I have never seen sickling -- certainly

## Transcript of the Sheku Bayoh Inquiry

1           significant sickling from a post mortem point of view.  
2           I've never been involved in any cases that have had  
3           either sickle cell disease or sickle cell trait before,  
4           hence why I didn't think about it in this case, which  
5           I probably should have done. There are genetic  
6           predispositions and it does happen in particular races  
7           as well so it is something that I am now aware of that  
8           I would certainly look for in the future in the correct  
9           race.

10          Q. So not something you have seen yourself in any of the  
11           post mortems that you have done?

12          A. No, and this case was obviously reviewed by Dr Bouhaidar  
13           and all of the members of my department, and none of us  
14           at the time thought this is something that we should be  
15           thinking about.

16          Q. Now has your practice changed in relation to that?

17          A. It will do. As I say, I haven't had the opportunity for  
18           it to require changing but it is certainly something  
19           that is now in the memory to consider, if it's in the  
20           correct set of circumstances.

21          Q. I think in your Inquiry statement at paragraph 108 you  
22           say that was a learning point for us all.

23          A. Definitely, yes.

24          Q. Yes. You have also -- have you had a chance -- you have  
25           been asked, I should say, about the significance, if

## Transcript of the Sheku Bayoh Inquiry

1           any, or whether that sickle cell trait has had any  
2           impact on the explanation for the death of Mr Bayoh.  
3           I think you've been advised that other experts have  
4           considered this, Dr Elizabeth Soilleux and  
5           Professor Lucas?

6           A. Yes.

7           Q. We may hear further evidence from Lucas in due course in  
8           this hearing but can you tell us from your perspective  
9           what impact this element had in your consideration.  
10          It's obviously a new piece of information provided to  
11          you and I am interested in what you have made of that in  
12          terms of your original conclusions and the final  
13          post mortem report?

14          A. When you consider the circumstances of this case in  
15          terms of we are talking about the kind of acidosis and  
16          there is also information provided that Mr Bayoh was  
17          maybe -- before he came in contact with the police was  
18          running for a period of time which would also have used  
19          oxygen, would've started for his muscles to break down,  
20          and then during the period of restraint again with --  
21          there would be increase in oxygen requirements as kind  
22          of more acid is produced, so certainly from the scenario  
23          it is possible that a degree of sickling could have  
24          occurred. It is not something I can prove  
25          pathologically and I will defer to the professor who

## Transcript of the Sheku Bayoh Inquiry

1           sees a lot more of these cases --

2           Q. Lucas?

3           A. -- Professor Lucas. He sees a lot more of these cases  
4           because his practice is out of London and there are  
5           a lot more people who have this trait in that area.  
6           But -- so I think it definitely has to be considered in  
7           the cause of death but in terms of the importance of it,  
8           kind of referring back to what I was saying about how  
9           I look at what is important in causing death in terms of  
10          the drugs, the restraint, if I took everything else out  
11          of the equation would they still be involved in causing  
12          death, then potentially yes. Whereas sickle cell  
13          doesn't come as high in that sort of level of priority  
14          because had this -- had Mr Bayoh not been involved in  
15          this whole scenario with drugs and with restraint, the  
16          sickle cell wouldn't have mattered at all. It has only  
17          come into play because of everything else that is  
18          happening. So it's certainly not as important as the  
19          other factors because if you take the other factors out  
20          of the equation this man has not died because he has  
21          sickle cell trait.

22                 So that is kind of where -- it's certainly important  
23                 and it's very useful to know, especially from a family  
24                 point of view, from a genetic point of view and genetic  
25                 screening, but I don't think it is as important as those

## Transcript of the Sheku Bayoh Inquiry

1 other factors.

2 Q. Thank you. Yesterday you used an example of where  
3 someone has diabetes, an underlying health condition  
4 which doesn't directly add much to the explanation for  
5 their death.

6 A. Yes.

7 Q. You wouldn't put it in number 1a, b, c or d but you  
8 would put it in as number 2 to provide a full picture of  
9 that person's health?

10 A. Yes.

11 Q. In terms of sickle cell and the importance of  
12 sickle cell are you saying you would put it into number  
13 2?

14 A. Yes, I would ideally put it into part 2 as opposed to  
15 adding it to the narrative in part 1.

16 Q. So in light of this new information, if you were being  
17 asked to comment on your cause of death in your final  
18 post mortem report would it be 1a, as it exists, subject  
19 to adding in the struggle, and 2 would be the sickle  
20 cell trait?

21 A. Sickle cell trait, yes.

22 Q. Thank you.

23 Two things I would like to say. I want to ask you  
24 about Professor Lucas' comments in a moment but in terms  
25 of your understanding of what Mr Bayoh was doing in the

## Transcript of the Sheku Bayoh Inquiry

1           lead-up to arriving at Hayfield Road, you've talked  
2           about him running and you have mentioned the sort of  
3           exertion of that. Would it make a difference to your  
4           assessment importance of sickle cell trait if you knew  
5           that some people had described him as walking, some  
6           people had described him as running but for short  
7           periods, some people had described him as chasing cars.

8           The Chair's heard a lot of evidence from  
9           eyewitnesses, who have described walking briskly,  
10          walking with purpose, have used different expressions.  
11          I don't recall anyone describing the sort of exertion  
12          that would equate to climbing a mountain or running  
13          a marathon or anything like that. Would that make any  
14          difference to your assessment of sickle cell being at  
15          number 2?

16         A. If there was less information to say that he had  
17          undergone extreme exertion then I am not sure I would  
18          take it out of cause of death because it is still just  
19          a possible factor, it's not definitive. It is there, he  
20          definitely has it, so it probably wouldn't alter what  
21          I would say in terms of the cause of death but it may  
22          kind of to my mind make it even less significant than  
23          what I was thinking.

24         Q. Thank you. The Chair will hear more evidence about  
25          sickle cell but that, from your perspective as

## Transcript of the Sheku Bayoh Inquiry

1 a pathologist it would be less significant in the  
2 overall cause of death?

3 A. Yes, because the important thing is how he has been, how  
4 his overall system has been affected by whatever  
5 activity he has been undertaking, because ultimately  
6 that is when the sickle cell will begin to have  
7 a problem in his blood cells. So if that is not  
8 actually there in the first place then the problem  
9 wouldn't happen.

10 Again, like I say, the diagnosis of it at  
11 post mortem is very, very difficult because you can get  
12 sickling, even in normal scenarios.

13 Q. Just to turn to what Professor Lucas has been saying.  
14 We have an Inquiry statement from him. We've not heard  
15 his evidence yet but I would like to read out something  
16 he said, and see if you agree with this. So he says:

17 "I don't think sickle cell trait is quite as  
18 important as I thought it was perhaps back in 2018,  
19 partly influenced by lots of discussions I had with  
20 coroners in England about how we should be phrasing  
21 causes of death, what is important and what is less  
22 important, what goes into part 1 (which is the main  
23 thing) and what goes into part 2 as a contributor. If  
24 I was doing this case again now I would move reference  
25 to sickle cell trait to part 2 of the death certificate,

## Transcript of the Sheku Bayoh Inquiry

1 I would not frame the entire story of his death around  
2 sickle cell trait, I would just simply put that in on  
3 the end and as a small extra factor."

4 That was in paragraph 25, which we will hear about  
5 in due course.

6 A. Yes, I think that is very sensible and that's exactly --

7 Q. Would you agree with that?

8 A. I would agree with that completely, yes.

9 Q. Thank you. Before I leave Dr Soilleux and

10 Professor Lucas can I ask you one thing. Dr Soilleux --  
11 you were asked about this at paragraph 159 of your  
12 Inquiry statement -- she appears to have said at  
13 an earlier stage she thought that positional asphyxia  
14 was unlikely due to the short time period between  
15 Mr Bayoh's contact with the police and the commencement  
16 of his unconsciousness and the fact that sufficient  
17 other contributing factors to death were known to be at  
18 play for death to have occurred as a consequence of  
19 those contributing factors in the absence of positional  
20 asphyxia.

21 Can we look at your Inquiry statement, please,  
22 paragraph 159. And that is SBPI 00304. I think you say  
23 here in response to questions about this matter:

24 "I would completely disagree. You cannot take  
25 positional asphyxia out of equation, especially when you



## Transcript of the Sheku Bayoh Inquiry

1           have it in the context of all the other things that are  
2           going on. So, it might require less to be in that  
3           position for a reduced period of time because your heart  
4           is already under strain due [to] the drugs taken, and  
5           because you've already run around for a period of time  
6           and got a build-up of lactic acid. This is  
7           a multifactorial death, and we do not know what the main  
8           factor has been. I think all of the forensic  
9           pathologists that have been involved in this case would  
10          completely agree with that and have all completely  
11          agreed with that."

12                 Is this perhaps a distinction between your  
13           experience as a forensic pathologist and perhaps  
14           Dr Soilleux's experience, which is in relation to sickle  
15           cell trait?

16          A. Yes, I'm not sure that she is a forensic pathologist --

17          Q. She is not?

18          A. -- I am not sure of what her qualifications are. So  
19           absolutely, there have been several forensic  
20           pathologists that have agreed that you cannot take the  
21           positional asphyxia away in this case. So I would  
22           completely disagree with her comments.

23          Q. Thank you. I would like to move on to one or two other  
24           things that have been raised by experts, just to ask you  
25           to comment on them, and we've already dealt with these

## Transcript of the Sheku Bayoh Inquiry

1           in your Inquiry statement, just so the Chair is  
2           completely clear.

3           Can I ask you about some comments made by  
4           Steven Karch and I would like to look at your Inquiry  
5           statement, really paragraphs -- if we say paragraphs 122  
6           to 126. So if we go to just 121, let's just put this  
7           into context. I think you were given sight of a report  
8           by Dr Steven Karch, the reference is there, I won't take  
9           you to it, it's quoted in paragraph 121:

10          "I have been asked to comment on the following  
11          paragraph [at page 4]: 'High doses of nandrolone elicit  
12          cardio-toxic effects including cardiac remodelling and  
13          injury. There is also laboratory evidence that they may  
14          provoke arrhythmias. As myocardial remodelling of both  
15          ventricles was apparent on my examination of the heart  
16          it seems only reasonable to conclude that nandrolone  
17          contributed to that process, as did all of the other  
18          stimulant drugs. There is also evidence that by methods  
19          yet to be determined nandrolone facilitates the  
20          occurrence of myocardial arrhythmias, the apparent cause  
21          of Mr Bayoh's demise'.

22          "I completely disagree with what he says~..."

23          This is the start of paragraph 122:

24          "... we did not see what he was seeing in the heart,  
25          the heart was completely normal histologically."

## Transcript of the Sheku Bayoh Inquiry

1           To summarise, as I understand from Dr Karch he  
2           thought there were problems with the heart, pre-existing  
3           problems that he considered he could see in Mr Bayoh's  
4           heart.

5           A. Yes.

6           Q. I think your position is that you disagree with that and  
7           I think yesterday you gave evidence that you felt the  
8           heart was normal?

9           A. Yes.

10          Q. I would just really like you to explain why you disagree  
11          with Steven Karch?

12          A. He is basically seeing -- saying he is seeing changes  
13          down the microscope that show evidence of chronic drugs  
14          misuse. That is one of the reasons that we did such  
15          a detailed examination of the heart, as I detailed  
16          yesterday. The histology -- I look at heart histology,  
17          as I detailed yesterday, on pretty much every case that  
18          I do and will do that several times per week on cases.  
19          The heart histology I took was reviewed by myself, by  
20          Dr Bouhaidar, the second doctor on this case, by the  
21          other three forensic pathologists in my department, and  
22          was also reviewed by other witnesses including  
23          a professor of cardiac pathology,  
24          Professor Mary Sheppard, and none of us have seen what  
25          Dr Karch has seen. So I am not sure what he is looking

## Transcript of the Sheku Bayoh Inquiry

1           at but I categorically disagree that there is any  
2           chronic changes in the heart.

3       Q.   So if there is any suggestion that there were  
4           histological abnormalities that were apparently  
5           overlooked at the original autopsy what would you say to  
6           that?

7       A.   I'd say that that -- they have been checked and  
8           double-checked by several experts, one being a professor  
9           in cardiac pathology, and no one has seen any of those  
10          changes. So I think it has been triply, quadruply  
11          checked that what he is seeing is not present.

12      Q.   I think we mentioned Professor Mary Sheppard, who is  
13          a professor in cardiology, and I think she has provided  
14          an Inquiry statement to the Chair. I understand she  
15          says she has looked at 7,000 hearts and says this was  
16          a normal heart.

17      A.   Yes.

18      Q.   Is that the lady you're talking about?

19      A.   Yes, uh-huh.

20      Q.   Then I think -- can I ask you to look at 126, please.  
21          Can we just check -- can I just check 124. Yes. Keep  
22          going, thank you. 126:

23                 "In Dr Karch's report he is asked the question: what  
24                 is the physiological effect of the restraint of the  
25                 deceased in the circumstances of his arrest? And his

## Transcript of the Sheku Bayoh Inquiry

1           answer is that 'Given the details of this situation, the  
2           effect of physical restraint would have been  
3           de minimis'."

4           I described that earlier as something that is very  
5           trivial, very minor:

6           "He further considers that the restraint is  
7           irrelevant when considered in combination with the drugs  
8           and CS spray/PAVA."

9           You have already talked to us about those two  
10          elements:

11          "I'm asked to comment on this. Pathologically  
12          I cannot say whether the restraint used was adequate or  
13          excessive. However, at the end of the day he was  
14          restrained. He was in a position that would've hampered  
15          his breathing, hampered his heart, and he was  
16          intoxicated with drugs. As such, there was  
17          a combination of factors that all would've interplayed  
18          with each other and it was difficult to say what has  
19          been the more important factor. I think all of them  
20          together is important. They have all happened together  
21          and resulted in his death. It would be interesting to  
22          know what his actual qualifications are and background  
23          to be able to say such things."

24          If the suggestion is made that the restraint could  
25          be taken out of the picture completely, described as

## Transcript of the Sheku Bayoh Inquiry

1           de minimis, trivial, of no consequence whatsoever, what  
2           is your position on that?

3           A. I would completely disagree.

4           Q. Is that for all the reasons you've given earlier today?

5           A. Yes.

6           Q. Thank you. One final thing that I would like to ask  
7           you. We hope to hear from a Dr Cary at the end of this  
8           hearing. We have not heard from him yet but we have  
9           an Inquiry statement from him. I just want to ask you  
10          in relation to something he said. He has not given us  
11          a full explanation yet, but I would like to ask you  
12          about it.

13                 So it's at paragraph 143 of your Inquiry statement,  
14                 please. We can use that as a starting point. You will  
15                 see you have been asked questions about Dr Cary's report  
16                 here starting at 142 and you have been -- comments have  
17                 been made about that. If we look at 142, this is  
18                 a quote from Dr Cary's report:

19                 "In terms of any role for restraint, this cannot be  
20                 separately considered from struggling. As is commonly  
21                 the case in acute behavioural disturbances the deceased  
22                 displayed remarkable strength and stamina. Ongoing  
23                 restraint and struggling in these circumstances is very  
24                 likely to lead to significant metabolic disturbances  
25                 with early breakdown of muscle releasing potassium,

## Transcript of the Sheku Bayoh Inquiry

1           which can precipitate cardiac dysrhythmias and the  
2           development of metabolic acidosis."

3           Now we can see some elements there that are coming  
4           through already. We have talked to you about struggle,  
5           the significance of struggle, and you have commented on  
6           that. This is your response to that comment,  
7           paragraph 143:

8           "I have been asked whether I agree with this  
9           statement. Yes, definitely. I am asked whether  
10          Sheku Bayoh was at particular risk of metabolic  
11          disturbance and the development of metabolic acidosis  
12          due to his muscular build. I do not know if having more  
13          muscle bulk increases the chance of your breakdown to  
14          lactic acid. Common sense would say it probably does,  
15          but pathophysiologically I do not know if that would be  
16          the case. Perhaps a clinician would probably have to  
17          answer that absolutely categorically."

18          So in terms of your role as a pathologist, that is  
19          not something you can comment on?

20          A. No.

21          Q. And you have already explained you can't do a test for  
22          lactic acid or the levels of lactic acid in a person?

23          A. No, and we can't do a test for potassium levels either,  
24          as Dr Cary has indicated. That will -- those will be  
25          released from the cells but after death your cells begin

## Transcript of the Sheku Bayoh Inquiry

1 to break down and potassium is automatically released.  
2 So it's impossible to know definitively what someone's  
3 potassium level has been when they've died.

4 Q. Then can we look at paragraphs 150 to 151 of your  
5 Inquiry statement. You have been asked to explain what  
6 type of matters are normally put in part 2 of a death  
7 certificate:

8 "Things that are potential factors but not  
9 necessarily directly related. 'Potential contributing  
10 factors' is the best way of describing it."

11 That is what we have been talking today in relation  
12 to your diabetes example from yesterday and the sickle  
13 cell today?

14 A. Yes.

15 Q. "Potentially may have played a role in death but not as  
16 important, or we don't think are as important, as things  
17 that we have put in part 1. Those are the really  
18 important things that we put in part 1. If I was going  
19 to change the cause of death, even if it was going to be  
20 in part 1, it would probably be with a narrative as in  
21 what we have but 'in a man with sickle cell trait'."

22 Then further on:

23 "So often with part 1, if you like, if you take that  
24 out, would the person still have died? With this case  
25 it is multifactorial. Could Sheku Bayoh have died just



## Transcript of the Sheku Bayoh Inquiry

1 from the restraint? Potentially, yes. Could  
2 Sheku Bayoh have died potentially just because of drugs?  
3 Yes. Could Sheku Bayoh have died just because he had  
4 sickle cell trait? No."

5 I think earlier today you said if all you had was  
6 a person who had been restrained and they had died, that  
7 could be a cause of death?

8 A. Uh-huh.

9 Q. And if all you had was a person who had taken drugs and  
10 they had died, that could be a cause of death?

11 A. Yes.

12 Q. But here you see both contributing and you can't  
13 separate them out --

14 A. Yes.

15 Q. -- in terms of their importance?

16 A. Yes.

17 Q. But you don't think sickle cell trait of itself would be  
18 an explanation for the death?

19 A. Yes.

20 Q. I think there was one thing I should've asked you  
21 yesterday and I didn't, and I would like to do that  
22 before I finish. I asked you about the fractured rib  
23 and whether you would defer to Professor Freemont on the  
24 timings and that type of thing in relation to the rib.  
25 Would you also defer to him in relation to his

Transcript of the Sheku Bayoh Inquiry

1 experience and the extra stainings that he did in  
2 relation to the most likely mechanism?

3 A. Potentially, because the mechanism will depend on the  
4 timings as well. So, yes.

5 MS GRAHAME: Thank you. Could you just give me a moment,  
6 please. (Pause).

7 Thank you very much. I have no further questions.

8 LORD BRACADALE: Are there any Rule 9 applications? I am  
9 going to rise to consult with my Assessors in case there  
10 is anything further to be raised. I will let you know  
11 whether we can do that before lunch or whether we have  
12 to wait until 2 o'clock.

13 (12.53 pm)

14 (The Inquiry adjourned until 10.00 am on Thursday,  
15 11 May 2023)

16

17

18

19

20

21

22

23

24

25

# Transcript of the Sheku Bayoh Inquiry

## INDEX

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

DR KERRYANNE SHEARER (continued) .....1

Questions from MS GRAHAME (continued) .....1

## Transcript of the Sheku Bayoh Inquiry

1

2